|
Originally published In Press as doi:10.1074/jbc.M007210200 on September 7, 2000
J. Biol. Chem., Vol. 275, Issue 48, 37504-37509, December 1, 2000
Human Apolipoprotein C-I Accounts for the Ability of Plasma High
Density Lipoproteins to Inhibit the Cholesteryl Ester Transfer Protein
Activity*
Thomas
Gautier ,
David
Masson ,
Jean-Paul Pais
de Barros ,
Anne
Athias ,
Philippe
Gambert ,
Dominique
Aunis§,
Marie-Hélène
Metz-Boutigue§, and
Laurent
Lagrost ¶
From the Laboratoire de Biochimie des
Lipoprotéines-INSERM U498, Hôpital du Bocage, BP1542, 21034 Dijon Cedex, France and the § Laboratoire de Biologie de la
Communication Cellulaire-INSERM U338, Centre de Neurochimie du CNRS,
67084 Strasbourg Cedex, France
The aim of the present study was to identify the
protein that accounts for the cholesteryl ester transfer protein
(CETP)-inhibitory activity that is specifically associated with human
plasma high density lipoproteins (HDL). To this end, human HDL
apolipoproteins were fractionated by preparative polyacrylamide
gradient gel electrophoresis, and 30 distinct protein fractions with
molecular masses ranging from 80 down to 2 kDa were tested for
their ability to inhibit CETP activity. One single apolipoprotein
fraction was able to completely inhibit CETP activity. The N-terminal
sequence of the 6-kDa protein inhibitor matched the N-terminal sequence
of human apoC-I, the inhibition was completely blocked by specific
anti-apolipoprotein C-I antibodies, and mass spectrometry analysis
confirmed the identity of the isolated inhibitor with full-length human
apoC-I. Pure apoC-I was able to abolish CETP activity in a
concentration-dependent manner and with a high efficiency
(IC50 = 100 nmol/liter). The inhibitory potency of
total delipidated HDL apolipoproteins completely disappeared after a
treatment with anti-apolipoprotein C-I antibodies, and the apoC-I
deprivation of native plasma HDL by immunoaffinity chromatography
produced a mean 43% rise in cholesteryl ester transfer rates. The main
localization of apoC-I in HDL and not in low density lipoprotein in
normolipidemic plasma provides further support for the specific
property of HDL in inhibiting CETP activity.
*
This work was supported by the Université de
Bourgogne, the Conseil Régional de Bourgogne, and INSERM.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed. Tel.: 33 3 80 29 38 25; Fax: 33 3 80 29 36 61; E-mail:
laurent.lagrost@u-bourgogne.fr.
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
P. F. James, C. Dogovski, R. C. J. Dobson, M. F. Bailey, K. N. Goldie, J. A. Karas, D. B. Scanlon, R. A. J. O'Hair, and M. A. Perugini
Aromatic residues in the C-terminal helix of human apoC-I mediate phospholipid interactions and particle morphology
J. Lipid Res.,
July 1, 2009;
50(7):
1384 - 1394.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Anuurad, M. Yamasaki, N. Shachter, T. A. Pearson, and L. Berglund
ApoE and ApoC-I polymorphisms: association of genotype with cardiovascular disease phenotype in African Americans
J. Lipid Res.,
July 1, 2009;
50(7):
1472 - 1478.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Masson, X.-C. Jiang, L. Lagrost, and A. R. Tall
The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis
J. Lipid Res.,
April 1, 2009;
50(Supplement):
S201 - S206.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. He, D. J. Greene, M. Kinter, and R. E. Morton
Control of cholesteryl ester transfer protein activity by sequestration of lipid transfer inhibitor protein in an inactive complex
J. Lipid Res.,
July 1, 2008;
49(7):
1529 - 1537.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. P. Berbee, S. P. Mooijaart, A. J. M. de Craen, L. M. Havekes, D. van Heemst, P. C. N. Rensen, and R. G. J. Westendorp
Plasma Apolipoprotein CI Protects Against Mortality From Infection in Old Age
J. Gerontol. A Biol. Sci. Med. Sci.,
February 1, 2008;
63(2):
122 - 126.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Gautier, U. J. F. Tietge, R. Boverhof, F. G. Perton, N. Le Guern, D. Masson, P. C. N. Rensen, L. M. Havekes, L. Lagrost, and F. Kuipers
Hepatic lipid accumulation in apolipoprotein C-I-deficient mice is potentiated by cholesteryl ester transfer protein
J. Lipid Res.,
January 1, 2007;
48(1):
30 - 40.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Masson, J.-P. Pais de Barros, Z. Zak, T. Gautier, N. Le Guern, M. Assem, J. W. Chisholm, J. R. Paterniti Jr., and L. Lagrost
Human apoA-I expression in CETP transgenic rats leads to lower levels of apoC-I in HDL and to magnification of CETP-mediated lipoprotein changes
J. Lipid Res.,
February 1, 2006;
47(2):
356 - 365.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Dumont, T. Gautier, J.-P. P. de Barros, H. Laplanche, D. Blache, P. Ducoroy, J. Fruchart, J.-C. Fruchart, P. Gambert, D. Masson, et al.
Molecular Mechanism of the Blockade of Plasma Cholesteryl Ester Transfer Protein by Its Physiological Inhibitor Apolipoprotein CI
J. Biol. Chem.,
November 11, 2005;
280(45):
38108 - 38116.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. O. Kwiterovich Jr, S. L. Cockrill, D. G. Virgil, E. S. Garrett, J. Otvos, C. Knight-Gibson, P. Alaupovic, T. Forte, L. Zhang, Z. N. Farwig, et al.
A Large High-Density Lipoprotein Enriched in Apolipoprotein C-I: A Novel Biochemical Marker in Infants of Lower Birth Weight and Younger Gestational Age
JAMA,
April 20, 2005;
293(15):
1891 - 1899.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. P. Berbee, C. C. van der Hoogt, D. Sundararaman, L. M. Havekes, and P. C. N. Rensen
Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL
J. Lipid Res.,
February 1, 2005;
46(2):
297 - 306.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kolmakova, P. Kwiterovich, D. Virgil, P. Alaupovic, C. Knight-Gibson, S. F. Martin, and S. Chatterjee
Apolipoprotein C-I Induces Apoptosis in Human Aortic Smooth Muscle Cells via Recruiting Neutral Sphingomyelinase
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2004;
24(2):
264 - 269.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
J. S. Cohn, R. Batal, M. Tremblay, H. Jacques, L. Veilleux, C. Rodriguez, O. Mamer, and J. Davignon
Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism
J. Lipid Res.,
October 1, 2003;
44(10):
1976 - 1983.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Parini and L. L. Rudel
Is There a Need for Cholesteryl Ester Transfer Protein Inhibition?
Arterioscler. Thromb. Vasc. Biol.,
March 1, 2003;
23(3):
374 - 375.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. J. Barter, H. B. Brewer Jr, M. J. Chapman, C. H. Hennekens, D. J. Rader, and A. R. Tall
Cholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis
Arterioscler. Thromb. Vasc. Biol.,
February 1, 2003;
23(2):
160 - 167.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Conde-Knape, A. Bensadoun, J. H. Sobel, J. S. Cohn, and N. S. Shachter
Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase
J. Lipid Res.,
December 1, 2002;
43(12):
2136 - 2145.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. S. Cohn, M. Tremblay, R. Batal, H. Jacques, L. Veilleux, C. Rodriguez, L. Bernier, O. Mamer, and J. Davignon
Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects
J. Lipid Res.,
October 1, 2002;
43(10):
1680 - 1687.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Bjorkegren, A. Silveira, S. Boquist, R. Tang, F. Karpe, M. G. Bond, U. de Faire, and A. Hamsten
Postprandial Enrichment of Remnant Lipoproteins With ApoC-I in Healthy Normolipidemic Men With Early Asymptomatic Atherosclerosis
Arterioscler. Thromb. Vasc. Biol.,
September 1, 2002;
22(9):
1470 - 1474.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Gautier, D. Masson, M. C. Jong, L. Duverneuil, N. Le Guern, V. Deckert, J.-P. P. de Barros, L. Dumont, A. Bataille, Z. Zak, et al.
Apolipoprotein CI Deficiency Markedly Augments Plasma Lipoprotein Changes Mediated by Human Cholesteryl Ester Transfer Protein (CETP) in CETP Transgenic/ApoCI-knocked Out Mice
J. Biol. Chem.,
August 23, 2002;
277(35):
31354 - 31363.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Fusegawa, K. L. Kelley, J. K. Sawyer, R. N. Shah, and L. L. Rudel
Influence of dietary fatty acid composition on the relationship between CETP activity and plasma lipoproteins in monkeys
J. Lipid Res.,
November 1, 2001;
42(11):
1849 - 1857.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|